» Articles » PMID: 2544364

Chemotherapy of Small Cell Lung Cancer

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 1989 Jul 1
PMID 2544364
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Selection of appropriate treatment is now possible on the basis of prognostic indices. For patients with a "poor" prognosis, therapy should be minimally toxic, for palliative purposes only. For patients with a "good" prognosis, intensive treatment is recommended with combinations comprised from C, A, V, VP-16, and CP. For patients obtaining a remission, consolidation is recommended with radiation treatment if this has not been part of the initial induction program with or without chemotherapy. Consolidation may be intensified by using high-dose chemotherapy in association with autologous bone marrow transplantation or possibly the use of hematopoietic growth factors. The major problem limiting further improvements in survival in this disease remains the emergence of drug resistance, which is now the subject of intensive investigations both in the laboratory and in the clinic.

Citing Articles

High expression of class III β-tubulin in small cell lung carcinoma.

Powell S, Kaizer A, Koopmeiners J, Iwamoto C, Klein M Oncol Lett. 2014; 7(2):405-410.

PMID: 24396456 PMC: 3881941. DOI: 10.3892/ol.2013.1734.


Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.

Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y PLoS One. 2009; 4(11):e7835.

PMID: 19915681 PMC: 2773043. DOI: 10.1371/journal.pone.0007835.